Skip to content
value.today

Prologis, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Fewer than two of the last three years have both cash from operations and capital spending on file.

P/EP/E of REIT - Industrial: $47.8 B to $93.1 B, median $67.6 BPrice to salesPrice to sales of REIT - Industrial: $70.1 B to $100.6 B, median $73.1 BPrice to bookPrice to book of REIT - Industrial: $62.8 B to $154.3 B, median $106.4 B$0 M$41.7 B$83.3 B$125.0 B$166.6 BMarket value $118.1 B

Your own DCF model

A full discounted-cash-flow model of Prologis, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry REIT - Industrial

Multiples of its companies with a market value at most 60 days old, times Prologis, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Prologis, Inc.Applied toValue (25th to 75th)Companies
P/E14.3× / 20.3× / 28.0×31.8×net income $3.3 B$47.8 B to $93.1 B12
Price to sales8.0× / 8.3× / 11.4×13.2×revenue $8.8 B$70.1 B to $100.6 B13
Price to book1.2× / 2.0× / 2.9×2.2×book equity $53.2 B$62.8 B to $154.3 B11

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Prologis, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

31.1×

Now below its median of 34.3×; range 25.7× to 76.7× over 30 months.

0×19×38×58×77×2020202120222023202420252026P/E 31×Median 34×

Price to sales

13.2×

Now below its median of 13.8×; range 11.7× to 25.6× over 30 months.

0×6×13×19×26×2020202120222023202420252026Price to sales 13×Median 14×

Price to book

2.2×

Now close to its median of 2.2×; range 1.8× to 3.6× over 30 months.

0×1×2×3×4×2020202120222023202420252026Price to book 2×Median 2×

as of Oct 23, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 23, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$8.8 B$3.3 B$5.0 B——$33.9 BSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$8.2 B$3.7 B$4.9 B——$29.6 BSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$8.0 B$3.1 B$5.4 B——$28.5 BSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$6.0 B$3.4 B$4.1 B——$23.6 BSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$4.8 B$2.9 B$3.0 B——$-341 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$4.4 B$1.5 B$2.9 B——$16.3 BSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $118.1 B on Oct 23, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.